IgA Nephropathy
Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option

In this podcast, Dr. Edgar Lerma and Dr. Dana Rizk discuss IgA nephropathy (IgAN) and the key data on sparsentan from the phase 3 PROTECT trial.

Go to PROTECT Podcast

Rare Kidney Disease Show
Talking Glomerular Nephropathies
Exciting Times Ahead

The Rare Kidney Disease Show is your primary source for cutting-edge insights, expert perspectives, and pivotal updates in nephrology.

Go to RKD Show